Table 1:

The policy assumptions relevant to PAVD use and modeled scenarios

Model assumption	Base case	Alternatives
Homotypic OPV allowed for oSIAs after OPV cessation of each type	entire time horizon
IPV use in routine immunization after the cessation of last OPV serotype	entire time horizon
bOPV cessation time	May 1, 2027
PAVD introduction time	NA	bOPV cessation
PAVD effectiveness	0%	40%, 90%
PAVD use approach	no PAVD	passive*, active**

Notes:

^*screening identifies 50% of iVDPV excreters with iVAPP and treats them with PAVDs with 40% effectiveness

^**screening identifies 90% of all iVDPV excreters and treats them with PAVDs with 90% effectiveness

Abbreviations:bOPV, bivalent OPV (types 1 and 3); IPV, inactivated poliovirus vaccine; OPV, oral poliovirus vaccine; oSIAs, outbreak supplemental immunization activities; PAVD, polio antiviral drug